Latest News and Press Releases

First presentation of detailed Phase 2 results following previous positive topline announcement that study of NTLA-2002 met primary and all secondary endpoints Intellia to host investor webcast on...

CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarterSelected...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

NTLA-3001 is a potential one-time gene editing treatment that may normalize AAT protein levels and halt the progression of lung disease associated with alpha-1 antitrypsin deficiency (AATD)NTLA-3001...

CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28...

CAMBRIDGE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...